Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | KSQ-004EX |
| Trade Name | |
| Synonyms | KSQ004EX|KSQ 004EX |
| Drug Descriptions |
KSQ-004EX comprises autologous tumor infiltrating lymphocytes (TILs) engineered to harbor inactivation of SOCS1 and Regnase-1, which potentially induces cytotoxicity in tumor cells and enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C210629 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Aldesleukin + KSQ-004EX | Aldesleukin KSQ-004EX | 0 | 1 |
| KSQ-004EX | KSQ-004EX | 0 | 1 |